Method for treating cancer patients with severe renal dysfunction

Abstract

A method for treating cancer in patients with a creatinine clearance of 15 mL / min or greater and less than 30 mL / min, comprising dividing a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, at a dose of 30 to 50 mg / m² / day as FTD equivalent, in two to four administrations per day and orally administering to the patient.